Other Events
ESMO Press Releases
On October 21, 2018, NuCana plc (the “Company”) issued a press release announcing combined results from cohorts one and two of its Phase Ib trial of Acelarin in patients with locally advanced or metastatic biliary tract cancer to determine its optimal dose in combination with cisplatin, referred to as theABC-08 Study, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.
On October 22, 2018, the Company issued a press release announcing the presentation of additional data from its Phase I clinical study ofNUC-3373, its ProTide transformation of the active anti-cancer metabolite of5-fluorouracil(5-FU), in patients with advanced solid tumors, at ESMO 2018. The press release is attached as Exhibit 99.2 hereto and is incorporated by reference herein.
Information in the attached Exhibits 99.1 and 99.2 are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
Business Update
The Company is filing a business update for the purpose of supplementing and updating the description of its business contained in the Company’s prior public filings with the Securities and Exchange Commission (the “SEC”), including those discussed under the heading “Item 4. Business” in the Company’s Annual Report on Form20-F for the year ended December 31, 2017, filed with the SEC on March 22, 2018. The updated disclosures are filed herewith as Exhibit 99.3 and are incorporated herein by reference.
The information in the attached Exhibit 99.3 shall be deemed to be incorporated by reference into (i) the Company’s Registration Statement on FormS-8 (File No.333-223476) and any related prospectuses and (ii) the Company’s Registration Statement on FormF-3 (File No.333-227624) and any related prospectuses, as such Registration Statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
